Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype

Molecular Therapy

Volumn 16, Issue 11, 2008, Pages 1865-1872

  Dobrikova, Elena Y ^a   Broadt, Trevor ^b   Poiley Nelson, Judith ^b   Yang, Xiaoyi ^b   Soman, Gopalan ^b   Giardina, Steve ^b   Harris, Ray ^b   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MOLECULAR MARKER; RECOMBINANT ONCOLYTIC POLIOVIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EVOLUTIONARY ADAPTATION; GENE REPLICATION; GENETIC MARKER; GENETIC STABILITY; GENOTYPE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; TEMPERATURE SENSITIVITY; TUMOR GROWTH; TUMOR REGRESSION; VIROTHERAPY;

ANIMALS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POLIOVIRUS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; POLIOVIRUS;

EID: 54949090721     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.184     Document Type: Article

References (33)

1. Lorence, RM, Reichard, KW, Katubig, BB, Reyes, HM, Phuangsab, A, Mitchell, BR et al. (1994). Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86: 1228-1233.
2. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6 821-825.
3. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
4. Andreansky, SS, He, B, Gillespie, GY, Soroceanu, L, Markert, J, Chou, J et al. (1996). The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93: 11313-11318.
5. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
6. Waehler, R, Russell, SJ and Curiel, DT (2007). Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587.
7. Domingo, E and Holland, JJ (1992). Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet Eng 14: 13-31.
8. Pfeiffer, JK and Kirkegaard, K (2005). Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 1: E11.
9. Vignuzzi, M, Stone, JK, Arnold, JJ, Cameron, CE and Andino, R (2006). Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344-348.
10. Gromeier, M, Lachmann, S, Rosenfeld, MR, Gutin, PH and Wimmer, E (2000). Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97: 6803-6808.
11. Merrill, MK, Bernhardt, G, Sampson, JH, Wikstrand, CJ, Bigner, DD and Gromeier, M (2004). Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-oncol 6: 208-217.
12. Dobrikova, E, Florez, P, Bradrick, S and Gromeier, M (2003). Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3′ nontranslated region. Proc Natl Acad Sci USA 100: 15125-15130.
13. Minor, PD, Macadam, AJ, Stone, DM and Almond, JW (1993). Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21: 357-363.
14. Paul, AV, Mugavero, J, Yin, J, Hobson, S, Schultz, S, van Boom, JH et al. (2000). Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272 72-84.
15. Wimmer, E, Hellen, CU and Cao, X (1993). Genetics of poliovirus. Annu Rev Genet 27: 353-436.
16. Merrill, MK, Dobrikova, EY and Gromeier, M (2006). Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J Virol 80: 3147-3156.
17. Merrill, MK and Gromeier, M (2006). The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol 80: 6936-6942.
18. Bullard, DE, Schold, SC, Bigner, SH and Bigner, DD (1981). Growth and chemotherapeutic response in athymic mice of tumors arising from human gliomaderived cell lines. J Neuropathol Exp Neurol 40: 410-427.
19. World Health Organization. (2002). Recommendations for the Production and Control of Poliomyelitis Vaccine (Oral). WHO: Geneva. Technical Report Series, No. 904.
20. Cello, J, Toyoda, H, Dejesus, N, Dobrikova, EY, Gromeier, M and Wimmer, E (2008). Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J Med Virol 80: 352-359.
21. Macadam, AJ, Ferguson, G, Burlison, J, Stone, D, Skuce, R, Almond, JW et al. (1992). Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189: 415-422.
22. Macadam, AJ, Pollard, SR, Ferguson, G, Dunn, G, Skuce, R, Almond, JW et al. (1991). The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181: 451-458.
23. Gromeier, M, Alexander, L and Wimmer, E (1996). Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 93: 2370-2375.
24. Gromeier, M, Bossert, B, Arita, M, Nomoto, A and Wimmer, E (1999). Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 73: 958-964.
25. Campbell, SA, Lin, J, Dobrikova, EY and Gromeier, M (2005). Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J Virol 79: 6281-6290.
26. Rettig, WJ, Spengler, BA, Chesa, PG, Old, LJ and Biedler, JL (1987). Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res 47: 1383-1389.
27. Ross, RA, Spengler, BA and Biedler, JL (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71: 741-747.
28. Shaw, G, Morse, S, Ararat, M and Graham, FL (2002). Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16: 869-871.
29. Nomoto, A, Omata, T, Toyoda, H, Kuge, S, Horie, H, Kataoka, Y et al. (1982). Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci USA 79: 5793-5797.
30. Toyoda, H, Yin, J, Mueller, S, Wimmer, E and Cello, J (2007). Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67: 2857-2864.
31. World Health Organization. (1990). Manual of Laboratory Methods for Testing the Potency of Final Vaccines Used in the WHO Expanded Programme on Immunization. WHO: Geneva. Technical Report Series, No. 800.
32. Florez de Sessions, P, Dobrikova, E and Gromeier, M (2007). Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD. J Virol 81: 8396-8405.
33. Dufresne, AT and Gromeier, M (2004). A nonpolio enterovirus with respiratory tropism causes poliomyelitis in intercellular adhesion molecule 1 transgenic mice. Proc Natl Acad Sci USA 101: 13636-13641.